Healthcare stocks, led by biotech firms Recursion and Sana, show growth potential beyond AI hype in 2027.

Healthcare stocks are gaining attention in 2026 as investors look beyond the AI boom, with biotechnology companies like Recursion Pharmaceuticals and Sana Biotechnology offering promising growth. Recursion's AI-driven drug discovery shows strong clinical trial results for cancer treatments, while Sana advances engineered cell therapies for diabetes and cancer despite financial challenges. Both companies have significant catalysts expected in 2027, but their stocks have declined sharply in 2026, indicating high risk and potential reward for investors.

Recursion Pharmaceuticals (RXRX) trades at USD 3.59 with a 1-day gain of 0.84%, while Sana Biotechnology (SANA) is priced at USD 2.38, down 2.06% as of Nov 11, 2026 23:02 WIB. On Pluang, RXRX sees 100% buy order activity and a market cap of $2.24 billion, contrasting with SANA's balanced buy-sell activity and a market cap of $729.61 million. These figures highlight different investor sentiments on these healthcare stocks at this moment.